This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Despite strong evidence that it is efficacious, chemoprevention has been underused in eligible women. Reasons offered not to adopt and initiate strategies to reduce the risk of breast cancer include the fear of adverse effects, medication costs, lack of reasonably accurate and feasible methods for assessing an individual's personal risk, and lack of established risk thresholds that maximize benefit and minimize harms. The article by Macdonald and colleagues remind us that the problem of lack of uptake of risk-reducing medications for breast cancer remains a worldwide clinical challenge despite endorsements from national and international organizations that recommend the use of risk-reducing medications for breast cancer with level I evidence. Several strategies are suggested to improve uptake and utilization of safe and effective chemoprevention medications with high therapeutic indices.
See related article by Macdonald et al., p. 131
Footnotes
Cancer Prev Res 2021;14:1–4
- Received October 21, 2020.
- Revision received October 27, 2020.
- Accepted November 3, 2020.
- Published first November 11, 2020.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
Volume 14, Issue 1
